Treatment Options for HRR-Negative mCRPC After Docetaxel and Abiraterone Progression
For patients with HRR-negative metastatic castration-resistant prostate cancer who have progressed on both docetaxel and abiraterone, cabazitaxel is the preferred next-line therapy, with 177Lu-PSMA-617 radioligand therapy as an alternative option if the patient is PSMA-positive. 1
Primary Treatment Recommendation: Cabazitaxel
The 2025 ASCO guidelines provide the strongest evidence for cabazitaxel in this exact clinical scenario. Cabazitaxel plus prednisone demonstrated superior outcomes compared to switching to a second androgen receptor pathway inhibitor (ARPI) in the CARD trial, with significant improvements in both progression-free survival (PFS HR 0.54,95% CI 0.40-0.73) and overall survival (OS HR 0.64,95% CI 0.46-0.89; median OS 13.6 vs 11.0 months). 1 This represents a 2.6-month survival advantage with cabazitaxel over sequential ARPI therapy.
The TROPIC trial further validates cabazitaxel's efficacy in post-docetaxel patients, showing OS benefit compared to mitoxantrone (HR 0.70,95% CI 0.59-0.83). 1, 2
Key point: Since your patient is HRR-negative, PARP inhibitors (olaparib, rucaparib) are NOT indicated, as these agents specifically require HRR gene alterations (particularly BRCA1/2) for efficacy. 1
Alternative Option: 177Lu-PSMA-617 Radioligand Therapy
If the patient has PSMA-positive imaging, 177Lu-PSMA-617 is a highly effective alternative, particularly for those who may not tolerate additional chemotherapy. The VISION trial demonstrated substantial benefits in patients previously treated with both ARPI and docetaxel:
- PFS: HR 0.40 (95% CI 0.28-0.56)
- OS: HR 0.62 (95% CI 0.52-0.74)
The 2025 ASCO guidelines specifically list this as a preferred option for PSMA-positive patients post-ARPI and docetaxel. 1
Treatment Selection Algorithm
Step 1: Assess PSMA Status
- Order PSMA PET imaging if not already done
- PSMA-positive → Consider 177Lu-PSMA-617 vs cabazitaxel based on patient factors below
- PSMA-negative or unavailable → Proceed to cabazitaxel
Step 2: Evaluate Patient Fitness for Chemotherapy
- Good performance status (ECOG 0-1), adequate organ function → Cabazitaxel is preferred
- Poor performance status (ECOG ≥2), significant comorbidities, patient preference against chemotherapy → 177Lu-PSMA-617 if PSMA-positive
Step 3: Consider Special Clinical Situations 1
- Bone-only symptomatic disease: Radium-223 (though less effective than cabazitaxel or PSMA therapy)
- Oligometastatic progression: Radiation therapy or surgery after multidisciplinary discussion
- MSI-H/dMMR tumors (rare in prostate cancer): Pembrolizumab
- Indolent disease (slow PSA rise, asymptomatic): Sipuleucel-T
What NOT to Use
Avoid sequential ARPI therapy (enzalutamide after abiraterone or vice versa) in this setting. The CARD trial definitively showed cabazitaxel superiority over second-line ARPI, and cross-resistance between ARPIs is well-established. 1 Real-world data confirm that second ARPI use results in lower response rates. 1
Do not use PARP inhibitors (olaparib, rucaparib) in HRR-negative patients—these require confirmed HRR gene alterations for benefit. 1
Critical Caveats
Confirm HRR-negative status: Ensure comprehensive genomic testing was performed (germline and somatic), as approximately 20-30% of mCRPC patients harbor HRR mutations. 1 Missing a BRCA1/2 mutation would eliminate PARP inhibitor options that could provide substantial benefit.
Monitor for cabazitaxel toxicity: Neutropenia is the dose-limiting toxicity. Prophylactic G-CSF should be considered, particularly in older patients or those with prior extensive chemotherapy. 2
PSMA imaging timing: If considering 177Lu-PSMA-617, ensure imaging is performed before initiating cabazitaxel, as chemotherapy may temporarily affect PSMA expression.
Avoid radium-223 with abiraterone: The ERA-223 trial showed increased fractures and mortality when combining these agents. 1 Since your patient already received abiraterone, this is less relevant, but radium-223 monotherapy remains an option only for symptomatic bone-only disease.
Practical Implementation
For cabazitaxel: 25 mg/m² IV every 3 weeks with prednisone 10 mg daily. Consider dose reduction to 20 mg/m² in elderly or frail patients.
For 177Lu-PSMA-617: 7.4 GBq IV every 6 weeks for up to 6 cycles, requires PSMA-positive imaging and adequate organ function.
Both options maintain androgen deprivation therapy throughout treatment.